CN115444822B - Ginsenoside epirubicin liposome, and preparation method and application thereof - Google Patents
Ginsenoside epirubicin liposome, and preparation method and application thereof Download PDFInfo
- Publication number
- CN115444822B CN115444822B CN202110652144.5A CN202110652144A CN115444822B CN 115444822 B CN115444822 B CN 115444822B CN 202110652144 A CN202110652144 A CN 202110652144A CN 115444822 B CN115444822 B CN 115444822B
- Authority
- CN
- China
- Prior art keywords
- ginsenoside
- epirubicin
- solution
- liposome
- aqueous solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002502 liposome Substances 0.000 title claims abstract description 242
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 title claims abstract description 205
- 229960001904 epirubicin Drugs 0.000 title claims abstract description 191
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 title claims abstract description 190
- 229930182494 ginsenoside Natural products 0.000 title claims abstract description 132
- 229940089161 ginsenoside Drugs 0.000 title claims abstract description 129
- 238000002360 preparation method Methods 0.000 title claims abstract description 35
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 80
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 46
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 40
- RWXIFXNRCLMQCD-JBVRGBGGSA-N (20S)-ginsenoside Rg3 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RWXIFXNRCLMQCD-JBVRGBGGSA-N 0.000 claims description 116
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 97
- 239000007864 aqueous solution Substances 0.000 claims description 94
- 239000000243 solution Substances 0.000 claims description 87
- 238000005538 encapsulation Methods 0.000 claims description 66
- 238000000034 method Methods 0.000 claims description 66
- 239000003814 drug Substances 0.000 claims description 64
- 239000012266 salt solution Substances 0.000 claims description 52
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 45
- MWWSFMDVAYGXBV-FGBSZODSSA-N (7s,9s)-7-[(2r,4s,5r,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydron;chloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-FGBSZODSSA-N 0.000 claims description 43
- 229960003265 epirubicin hydrochloride Drugs 0.000 claims description 43
- 238000000502 dialysis Methods 0.000 claims description 42
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 35
- 239000002245 particle Substances 0.000 claims description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 29
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 29
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 29
- 239000008103 glucose Substances 0.000 claims description 27
- WEPNHBQBLCNOBB-FZJVNAOYSA-N sucrose octasulfate Chemical compound OS(=O)(=O)O[C@@H]1[C@H](OS(O)(=O)=O)[C@H](COS(=O)(=O)O)O[C@]1(COS(O)(=O)=O)O[C@@H]1[C@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H](COS(O)(=O)=O)O1 WEPNHBQBLCNOBB-FZJVNAOYSA-N 0.000 claims description 22
- 239000000644 isotonic solution Substances 0.000 claims description 21
- 239000012528 membrane Substances 0.000 claims description 21
- CKUVNOCSBYYHIS-UHFFFAOYSA-N (20R)-ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CCC3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1O CKUVNOCSBYYHIS-UHFFFAOYSA-N 0.000 claims description 18
- JCEGHWINSDHXCP-UHFFFAOYSA-N C(CS(=O)(=O)O)S(=O)(=O)O.C(C)N(CC)CC Chemical compound C(CS(=O)(=O)O)S(=O)(=O)O.C(C)N(CC)CC JCEGHWINSDHXCP-UHFFFAOYSA-N 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 16
- 230000036571 hydration Effects 0.000 claims description 14
- 238000006703 hydration reaction Methods 0.000 claims description 14
- QHYIGPGWXQQZSA-UHFFFAOYSA-N azane;methanesulfonic acid Chemical compound [NH4+].CS([O-])(=O)=O QHYIGPGWXQQZSA-UHFFFAOYSA-N 0.000 claims description 13
- 238000001125 extrusion Methods 0.000 claims description 13
- 239000008346 aqueous phase Substances 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 12
- 238000011049 filling Methods 0.000 claims description 10
- CKUVNOCSBYYHIS-IRFFNABBSA-N (20S)-ginsenoside Rh2 Chemical compound O([C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CKUVNOCSBYYHIS-IRFFNABBSA-N 0.000 claims description 9
- -1 propane disulfonate triethylamine Chemical compound 0.000 claims description 9
- 238000000265 homogenisation Methods 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 238000002604 ultrasonography Methods 0.000 claims description 8
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical class CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 claims description 7
- XPHQOYGOTSGXDN-UHFFFAOYSA-N diazanium;ethane-1,2-disulfonate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)CCS([O-])(=O)=O XPHQOYGOTSGXDN-UHFFFAOYSA-N 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 229930006000 Sucrose Natural products 0.000 claims description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- KQYREKISXCBRQB-UHFFFAOYSA-N n,n-diethylethanamine;methanesulfonic acid Chemical compound CS(O)(=O)=O.CCN(CC)CC KQYREKISXCBRQB-UHFFFAOYSA-N 0.000 claims description 6
- 239000005720 sucrose Substances 0.000 claims description 6
- KWDWBAISZWOAHD-MHOSXIPRSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-2-[[(3s,5r,8r,9r,10r,12r,13r,14r,17s)-12-hydroxy-4,4,8,10,14-pentamethyl-17-(6-methylhepta-1,5-dien-2-yl)-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]o Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4C(=C)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KWDWBAISZWOAHD-MHOSXIPRSA-N 0.000 claims description 5
- NJUXRKMKOFXMRX-RNCAKNGISA-N Ginsenoside Rg5 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4C(/C)=C/CC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NJUXRKMKOFXMRX-RNCAKNGISA-N 0.000 claims description 5
- KWDWBAISZWOAHD-UHFFFAOYSA-N Ginsenoside Rk1 Natural products CC(C)=CCCC(=C)C1CCC(C2(CCC3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O KWDWBAISZWOAHD-UHFFFAOYSA-N 0.000 claims description 5
- BHCDBPBXKGCSGD-UHFFFAOYSA-N diazanium propane-1,3-disulfonate Chemical compound C(CS(=O)(=O)[O-])CS(=O)(=O)[O-].[NH4+].[NH4+] BHCDBPBXKGCSGD-UHFFFAOYSA-N 0.000 claims description 5
- NJUXRKMKOFXMRX-AXUZFSSLSA-N ginsenoside Rg5 Natural products CC(=CCC=C(C)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]3[C@@]4(C)CC[C@@H](O[C@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O[C@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)C(C)(C)[C@@H]4CC[C@@]23C)C NJUXRKMKOFXMRX-AXUZFSSLSA-N 0.000 claims description 5
- NJUXRKMKOFXMRX-UHFFFAOYSA-N ginsenoside Rz1 Natural products CC(C)=CCC=C(C)C1CCC(C2(CCC3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O NJUXRKMKOFXMRX-UHFFFAOYSA-N 0.000 claims description 5
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 5
- 239000011148 porous material Substances 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 4
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical class CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 229930182555 Penicillin Natural products 0.000 claims description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 4
- 229940049954 penicillin Drugs 0.000 claims description 4
- 239000008347 soybean phospholipid Chemical class 0.000 claims description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 238000005520 cutting process Methods 0.000 claims description 3
- 238000007710 freezing Methods 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 239000004417 polycarbonate Substances 0.000 claims description 3
- 229920000515 polycarbonate Polymers 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- SRLOHQKOADWDBV-NRONOFSHSA-M sodium;[(2r)-2,3-di(octadecanoyloxy)propyl] 2-(2-methoxyethoxycarbonylamino)ethyl phosphate Chemical group [Na+].CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCCNC(=O)OCCOC)OC(=O)CCCCCCCCCCCCCCCCC SRLOHQKOADWDBV-NRONOFSHSA-M 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 206010000830 Acute leukaemia Diseases 0.000 claims description 2
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 claims description 2
- 238000009210 therapy by ultrasound Methods 0.000 claims description 2
- FRRMMWJCHSFNSG-UHFFFAOYSA-N diazanium;propanedioate Chemical compound [NH4+].[NH4+].[O-]C(=O)CC([O-])=O FRRMMWJCHSFNSG-UHFFFAOYSA-N 0.000 claims 2
- 238000010025 steaming Methods 0.000 claims 2
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 claims 1
- BAVYZALUXZFZLV-UHFFFAOYSA-O Methylammonium ion Chemical compound [NH3+]C BAVYZALUXZFZLV-UHFFFAOYSA-O 0.000 claims 1
- 238000001816 cooling Methods 0.000 claims 1
- JEUXZUSUYIHGNL-UHFFFAOYSA-N n,n-diethylethanamine;hydrate Chemical compound O.CCN(CC)CC JEUXZUSUYIHGNL-UHFFFAOYSA-N 0.000 claims 1
- ULWOJODHECIZAU-UHFFFAOYSA-N n,n-diethylpropan-2-amine Chemical compound CCN(CC)C(C)C ULWOJODHECIZAU-UHFFFAOYSA-N 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 23
- 230000008685 targeting Effects 0.000 abstract description 12
- 210000004881 tumor cell Anatomy 0.000 abstract description 5
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 description 51
- 238000002474 experimental method Methods 0.000 description 30
- 235000019441 ethanol Nutrition 0.000 description 27
- 238000011068 loading method Methods 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 18
- 238000002347 injection Methods 0.000 description 18
- 239000007924 injection Substances 0.000 description 18
- 239000012071 phase Substances 0.000 description 18
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 17
- 101001105486 Homo sapiens Proteasome subunit alpha type-7 Proteins 0.000 description 17
- 102100021201 Proteasome subunit alpha type-7 Human genes 0.000 description 17
- 229940090044 injection Drugs 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 14
- 230000003285 pharmacodynamic effect Effects 0.000 description 13
- 101100393884 Drosophila melanogaster Glut1 gene Proteins 0.000 description 10
- 101150058068 SLC2A1 gene Proteins 0.000 description 10
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 9
- 238000012377 drug delivery Methods 0.000 description 9
- 239000000463 material Substances 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 230000008901 benefit Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 230000000857 drug effect Effects 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- XIRZPICFRDZXPF-UHFFFAOYSA-N Ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CC(O)C3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O XIRZPICFRDZXPF-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 230000007059 acute toxicity Effects 0.000 description 4
- 231100000403 acute toxicity Toxicity 0.000 description 4
- 239000003012 bilayer membrane Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000010409 thin film Substances 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 3
- 229940009456 adriamycin Drugs 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 239000010408 film Substances 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- BBEUDPAEKGPXDG-UHFFFAOYSA-N protopanaxatriol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC3C4(C)CCC(O)C(C)(C)C4C(O)CC23C BBEUDPAEKGPXDG-UHFFFAOYSA-N 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 235000017709 saponins Nutrition 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 229940126902 Phlorizin Drugs 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 2
- 239000003777 experimental drug Substances 0.000 description 2
- 238000010812 external standard method Methods 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 229940093181 glucose injection Drugs 0.000 description 2
- 230000000887 hydrating effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 239000002052 molecular layer Substances 0.000 description 2
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- IOUVKUPGCMBWBT-UHFFFAOYSA-N phloridzosid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-UHFFFAOYSA-N 0.000 description 2
- IOUVKUPGCMBWBT-GHRYLNIYSA-N phlorizin Chemical compound O[C@@H]1[C@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-GHRYLNIYSA-N 0.000 description 2
- 235000019139 phlorizin Nutrition 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- CAXRKYFRLOPCAB-UHFFFAOYSA-N propane-1,1-disulfonic acid Chemical compound CCC(S(O)(=O)=O)S(O)(=O)=O CAXRKYFRLOPCAB-UHFFFAOYSA-N 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- 230000001360 synchronised effect Effects 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- AGBCLJAHARWNLA-UHFFFAOYSA-N (20R)-ginsenoside Rg2 Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C3C(C)(C)C(O)CCC3(C)C3C(C4(CCC(C4C(O)C3)C(C)(O)CCC=C(C)C)C)(C)C2)OC(CO)C(O)C1O AGBCLJAHARWNLA-UHFFFAOYSA-N 0.000 description 1
- RAQNTCRNSXYLAH-RFCGZQMISA-N (20S)-ginsenoside Rh1 Chemical compound O([C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@H]2C[C@@H](O)[C@H]3[C@@]([C@@]2(C1)C)(C)CC[C@@H]3[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RAQNTCRNSXYLAH-RFCGZQMISA-N 0.000 description 1
- PYXFVCFISTUSOO-HKUCOEKDSA-N (20S)-protopanaxadiol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C PYXFVCFISTUSOO-HKUCOEKDSA-N 0.000 description 1
- WMGBQZAELMGYNO-YMWSGFAJSA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[[(3s,5r,8r,9r,10r,12r,13r,14r,17s)-12-hydroxy-4,4,8,10,14-pentamethyl-17-(6-methylhepta-1,5-dien-2-yl)-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]oxane-3,4,5-triol Chemical compound O([C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4C(=C)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O WMGBQZAELMGYNO-YMWSGFAJSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- AGBCLJAHARWNLA-HQPVLIODSA-N 20(S)-ginsenoside Rg2 Natural products C[C@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2O[C@H]3C[C@]4(C)[C@H](C[C@@H](O)[C@@H]5[C@H](CC[C@@]45C)[C@@](C)(O)CCC=C(C)C)[C@@]6(C)CC[C@H](O)C(C)(C)[C@H]36)[C@H](O)[C@@H](O)[C@@H]1O AGBCLJAHARWNLA-HQPVLIODSA-N 0.000 description 1
- GHWSMQHJFMAATF-DSHMRAQASA-N 20(S)-protopanaxadiol Natural products CC(=CCC[C@@](O)(CO)[C@H]1CC[C@]2(C)[C@@H]1CC[C@H]3[C@@]2(C)CC[C@H]4C(C)(C)[C@@H](O)CC[C@]34CO)C GHWSMQHJFMAATF-DSHMRAQASA-N 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- 206010006189 Breast cancer in situ Diseases 0.000 description 1
- UZSCFVMBGQQWQY-UHFFFAOYSA-N COS(=O)=O Chemical compound COS(=O)=O UZSCFVMBGQQWQY-UHFFFAOYSA-N 0.000 description 1
- AGBCLJAHARWNLA-DQUQINEDSA-N Ginsenoside RG2 Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@@](C)(O)CCC=C(C)C)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O AGBCLJAHARWNLA-DQUQINEDSA-N 0.000 description 1
- RAQNTCRNSXYLAH-UHFFFAOYSA-N Ginsenoside Rh1 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(C3)C)(C)C1C(O)CC2C1(C)CCC(O)C(C)(C)C1C3OC1OC(CO)C(O)C(O)C1O RAQNTCRNSXYLAH-UHFFFAOYSA-N 0.000 description 1
- UZRSSXUIXNCYLP-UHFFFAOYSA-N Ginsenoside Rk2 Natural products CC(=CCCC(=C)C1CCC2(C)C1C(O)CC3C4(C)CCC(OC5CC(O)C(O)C(CO)O5)C(C)(C)C4CCC23C)C UZRSSXUIXNCYLP-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- AXUYHJMSEJPTPI-UHFFFAOYSA-N azane;4-hydroxybenzenesulfonic acid Chemical compound [NH4+].OC1=CC=C(S([O-])(=O)=O)C=C1 AXUYHJMSEJPTPI-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- PYXFVCFISTUSOO-UHFFFAOYSA-N betulafolienetriol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC(C(C)(O)CCC=C(C)C)C4C(O)CC3C21C PYXFVCFISTUSOO-UHFFFAOYSA-N 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 201000005389 breast carcinoma in situ Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000012771 intravital microscopy Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- RTKLULICMVRQMK-UHFFFAOYSA-N n,n-diethylethanamine;4-hydroxybenzenesulfonic acid Chemical compound CCN(CC)CC.OC1=CC=C(S(O)(=O)=O)C=C1 RTKLULICMVRQMK-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000012634 optical imaging Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000012809 post-inoculation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- SHCBCKBYTHZQGZ-CJPZEJHVSA-N protopanaxatriol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2[C@@H](O)C[C@@]3(C)[C@]4(C)CC[C@H]([C@@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C SHCBCKBYTHZQGZ-CJPZEJHVSA-N 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 102220042174 rs141655687 Human genes 0.000 description 1
- DAJSVUQLFFJUSX-UHFFFAOYSA-M sodium;dodecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCS([O-])(=O)=O DAJSVUQLFFJUSX-UHFFFAOYSA-M 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000004506 ultrasonic cleaning Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a ginsenoside epirubicin liposome, a preparation method and application thereof. The invention provides a ginsenoside epirubicin liposome (Ginposome-EPI) which comprises the following components in parts by weight: 5-15 parts of phospholipid, 0.1-4 parts of ginsenoside and 1 part of epirubicin salt; the ginsenoside epirubicin liposome does not comprise cholesterol. The ginsenoside epirubicin liposome has targeting effect and synergistic attenuation on tumor cells.
Description
Technical Field
The invention relates to a ginsenoside epirubicin liposome, a preparation method and application thereof.
Background
The liposome is a directional drug-carrying system, belongs to a special dosage form of a targeted drug-carrying system, and can embed drugs in nano-sized particles, wherein the particles are similar to double-molecular layer microvesicles in a biological membrane structure, enter a human body to be mainly phagocytized by reticuloendothelial systems, and change the in-vivo distribution of the encapsulated drugs, so that the drugs are mainly accumulated in targeted tissues, thereby improving the therapeutic index of the drugs, reducing the therapeutic dose of the drugs and reducing the toxicity of the drugs.
The liposome is a directional drug-carrying system, belongs to a special dosage form of a targeted drug-carrying system, and can embed drugs in nano-sized particles, wherein the particles are similar to double-molecular layer microvesicles in a biological membrane structure, enter a human body to be mainly phagocytized by reticuloendothelial systems, and change the in-vivo distribution of the encapsulated drugs, so that the drugs are mainly accumulated in targeted tissues, thereby improving the therapeutic index of the drugs, reducing the therapeutic dose of the drugs and reducing the toxicity of the drugs.
Three application patents of CN201610693884.2, CN201811447245.3 and CN201811447243.4 all disclose that a liposome prepared by taking ginsenoside as a membrane material and mainly taking a passive drug carrying method, namely a thin film evaporation method, has the technical advantages of stable quality, remarkable drug effect and the like of the related liposome after the liposome is coated with chemotherapeutic drugs such as paclitaxel and the like. The water-soluble medicine is more suitable for being prepared by adopting active medicine carrying methods and the like.
CN200380104235.5 and CN200380104175.7 disclose a preparation method of liposome active drug-carrying agent using phospholipid and cholesterol as membrane material and using ammonium sulfate as gradient.
CN201811532448.2, CN201811552395.0 and other patents disclose a liposome active drug-loading method using phospholipid and cholesterol as membrane materials and sucrose octasulfate triethylamine as gradient.
CN201811305299.6 discloses a method for preparing a membrane material from phospholipid and cholesterol, and from ammonium methylsulfonate, ammonium 4-hydroxybenzenesulfonate, triethylamine methylsulfonate, and triethylamine 4-hydroxybenzenesulfonate; the active liposome medicine carrying method with ammonium ethanedisulfonate, ammonium propanedisulfonate, triethylamine ethanedisulfonate, triethylamine propanedisulfonate, etc. as gradient.
In the prior art, the ginsenoside liposome can be prepared into a co-carried liposome of a poorly soluble drug by adopting a thin film evaporation method, but a water-soluble drug is generally prepared by adopting an active drug carrying method, wherein a bilayer membrane consists of phospholipid and cholesterol, an ionic salt solution such as ammonium sulfate, sucrose octasulfate triethylamine and the like is used as an inner water phase, and the water-soluble drug is loaded into the inner cavity of the liposome by adopting principles such as pH gradient and the like.
Therefore, how to select an optimal compound medicine compatibility and how to formulate an optimal preparation process so as to produce the ginsenoside epirubicin liposome with better medicine effect, lower toxicity, quality and other indexes meeting the medicine requirements so as to meet the medicine declaration requirements, and a great deal of research work and technical attack are needed.
Disclosure of Invention
The invention aims to solve the technical problem that the existing epirubicin liposome is single in type, and provides a ginsenoside epirubicin liposome, a preparation method and application thereof. The epirubicin liposome disclosed by the invention has the advantages of stable property, small particle size, high drug encapsulation efficiency, good in-vivo compatibility, good in-vivo drug release, better drug effect and lower toxicity. In addition, the preparation method of the ginsenoside epirubicin liposome is easy to realize and is beneficial to industrialization; can realize the optimization of the combination of the preparation process and the product performance.
The invention provides a ginsenoside epirubicin liposome (Ginposome-EPI) which comprises the following components in parts by weight: 5-15 parts of phospholipid, 0.1-4 parts of ginsenoside and 1 part of epirubicin salt; the ginsenoside epirubicin liposome does not comprise cholesterol.
In one embodiment of the present invention, the epirubicin salt may be an epirubicin salt obtained by ion exchange of epirubicin hydrochloride with a salt solution by a pH gradient method (wherein, the doxorubicin in the epirubicin salt and the anion in the salt solution form the doxorubicin salt); the salt solution can be sulfate aqueous solution, sulfonate aqueous solution or sucrose octasulfate aqueous solution; preferably, the salt solution is an ammonium sulfate aqueous solution, a sucrose octasulfate triethylamine aqueous solution, an ammonium methylsulfonate aqueous solution, a methyl sulfonic acid triethylamine aqueous solution, an ammonium ethanedisulfonate aqueous solution, an ammonium propanedisulfonate aqueous solution, an ethylene disulfonate triethylamine aqueous solution or an ethylene disulfonate triethylamine aqueous solution; more preferably, the salt solution is an aqueous solution of ammonium sulfate, an aqueous solution of sucrose octasulfate triethylamine, an aqueous solution of ammonium methylsulfonate or an aqueous solution of ethylene disulfonate triethylamine; such as an aqueous ammonium sulfate solution.
In one embodiment of the present invention, the ratio of the salt solution to the epirubicin hydrochloride may be 66.7-200 mL/g, such as 100mL/g.
In one embodiment of the present invention, the epirubicin salt may be epirubicin sulfate, epirubicin hydrochloride, sucrose octasulfate, methyl sulfonic acid epirubicin, epirubicin methyl sulfonic acid, epirubicin ethane disulfonic acid, epirubicin propane disulfonic acid, epirubicin ethane disulfonic acid, or epirubicin propane disulfonic acid; more preferably, the epirubicin salt is epirubicin sulfate, sucrose octasulfate epirubicin, epirubicin methylsulfonate or epirubicin disulfonate; such as epirubicin sulfate.
In one embodiment of the present invention, the ginsenoside epirubicin liposome forms a phospholipid membrane with the phospholipid.
In one embodiment of the invention, the phospholipid membrane further comprises PEG-DSPE.
In one aspect of the present invention, preferably, the inner side of the phospholipid membrane is an inner aqueous phase, the outer side of the phospholipid membrane is an outer aqueous phase, and the epirubicin is encapsulated in the inner aqueous phase; the epirubicin is water-insoluble epirubicin salt.
In one aspect of the present invention, preferably, the inner aqueous phase is a salt solution; the outer aqueous phase is preferably a physiological isotonic solution; for example, the physiological isotonic solution is a 5% aqueous dextrose solution or a 10% aqueous sucrose solution.
In one embodiment of the invention, the salt solution has a concentration of 0.05M to 0.975M; for example 0.05M, 0.1M, 0.2M, 0.3M, 0.325M, 0.65M, 0.975M or 0.16M.
In one embodiment of the invention, when the salt solution is an aqueous solution of sucrose octasulfate triethylamine, the salt solution has a concentration of 0.05M to 0.3M, for example, 0.1M, 0.2M or 0.3M.
In one embodiment of the present invention, when the salt solution is an aqueous solution of triethylamine ethanedisulfonate, the salt solution has a concentration of 0.16M to 0.325M.
In one embodiment of the present invention, when the salt solution is an aqueous solution of ammonium methylsulfonate, the concentration of the salt solution is 0.325M to 0.975M.
In one embodiment of the invention, when the salt solution is an aqueous ammonium sulfate solution, the salt solution has a concentration of 0.16M to 0.325M, for example, 0.325.
In one embodiment of the invention, the ginsenoside epirubicin liposome further comprises PEG-DSPE.
In one embodiment of the invention, the mass fraction of PEG-DSPE is 0.1-2 parts.
In the invention, PEG-DSPE is called polyethylene glycol-distearoyl phosphatidylethanolamine; the PEG-DSPE is PEG2000-DSPE.
In one embodiment of the invention, the epirubicin hydrochloride is 10mg/mL epirubicin hydrochloride aqueous solution.
In one embodiment of the present invention, the phospholipid is selected from one or more of hydrogenated phospholipid, egg yolk lecithin, soybean phospholipid and cephalin; preferably, the phospholipid is hydrogenated phospholipid or egg yolk lecithin.
In one scheme of the invention, the mass ratio of the epirubicin hydrochloride to the phospholipid can be 1:5-15; for example, the mass ratio of epirubicin hydrochloride to phospholipid is 1:10.
In one embodiment of the present invention, the ginsenoside is one or more selected from 20 (S) -ginsenoside Rg3, 20 (S) -ginsenoside Rh2, ginsenoside Rg5, ginsenoside Rk1 and ginsenoside Rp1, preferably, the ginsenoside is 20 (S) -ginsenoside Rg3, 20 (S) -ginsenoside Rh2.
In one embodiment of the invention, the HPLC purity of the ginsenoside is greater than or equal to 99%.
In one scheme of the invention, the mass ratio of the epirubicin salt to the ginsenoside can be 1:0.1-4; for example, the mass ratio of the epirubicin salt to the ginsenoside is 1:1 or 1:1.5.
In one embodiment of the present invention, the mass fraction of the phospholipid is 10 parts.
In one embodiment of the present invention, the mass fraction of the PEG-DSPE is 0.5 part
In one scheme of the invention, the mass fraction of the ginsenoside is 1 part.
In one scheme of the invention, the particle size D90 of the ginsenoside epirubicin liposome is less than or equal to 150nm.
In one embodiment of the present invention, the ginsenoside epirubicin liposome further comprises water.
In one embodiment of the present invention, the internal aqueous phase is a salt solution; the amount and type of the salt solution are as described above.
In one embodiment of the present invention, the inner aqueous phase is preferably an aqueous ammonium sulfate solution.
In one aspect of the invention, the external aqueous phase may be a physiological isotonic solution; for example, the physiological isotonic solution is a 5% aqueous dextrose solution or a 10% aqueous sucrose solution.
The invention also provides a preparation method of the ginsenoside epirubicin liposome, which comprises the following steps of;
step 1, dissolving phospholipid in a solvent, and adding a salt solution for hydration to obtain a solution A1;
step 2, which is scheme 1, scheme 2 or scheme 3;
Scheme 1 (high pressure homogenization) includes the steps of:
homogenizing the solution A1 obtained in the step 1 under high pressure, and controlling the particle size D90 to be less than 100nm to obtain a solution A2a;
scheme 2 (extrusion process) includes the steps of:
extruding the solution A1 obtained in the step 1 through all pore diameter extrusion plates in sequence, and controlling the particle diameter D90 to be less than 100nm to obtain a solution A2b;
scheme 3 (ultrasound) includes the steps of:
carrying out ultrasonic treatment on the solution A1 obtained in the step 1 to obtain a solution A2c;
step 3, dialyzing the solution A2a, A2b or A2c obtained in the step 2 in a dialysis bag containing the physiological isotonic solution to obtain a solution A3;
step 4, mixing the solution A3 obtained in the step 3 with an aqueous solution of epirubicin hydrochloride to obtain an A4 liposome;
and 5, mixing the A4 liposome obtained in the step 4 with ginsenoside in ethanol to obtain an A5 liposome.
In one embodiment of the present invention, the preparation method further includes step 6: dispersing the A5 liposome and the PEG-DSPE obtained in the step 5 in a physiological isotonic solution to obtain the ginsenoside epirubicin liposome.
In one embodiment of the present invention, the phospholipid is selected from one or more of hydrogenated phospholipid, egg yolk lecithin, soybean phospholipid and cephalin; preferably, the phospholipid is hydrogenated phospholipid or egg yolk lecithin.
In one embodiment of the present invention, the ginsenoside is one or more selected from 20 (S) -ginsenoside Rg3, 20 (S) -ginsenoside Rh2, ginsenoside Rg5, ginsenoside Rk1 and ginsenoside Rp1, preferably, the ginsenoside is 20 (S) -ginsenoside Rg3, 20 (S) -ginsenoside Rh2.
In one embodiment of the invention, the HPLC purity of the ginsenoside is greater than or equal to 99%.
In one scheme of the invention, the mass ratio of the epirubicin salt to the ginsenoside can be 1:0.1-4; for example, the mass ratio of the epirubicin salt to the ginsenoside is 1:1 or 1:1.5.
In one embodiment of the present invention, the mass ratio of the epirubicin salt to the phospholipid may be 1:5-15; for example, the mass ratio of epirubicin hydrochloride to phospholipid is 1:10.
In one embodiment of the present invention, in the step 1, the solvent is a conventional solvent for such reactions in the art; preferably, the solvent is ethanol; such as absolute ethanol.
In one embodiment of the present invention, in the step 1, the mass-to-volume ratio of the phospholipid to the solvent is 1 g/1-10 mL, for example, 1g/2mL.
In one embodiment of the present invention, in the step 1, the epirubicin salt may be epirubicin sulfate, epirubicin hydrochloride, sucrose octasulfate, epirubicin monomethylsulfonate, epirubicin propyldisulfonate, epirubicin epidisulfonate or epirubicin propyldisulfonate; more preferably, the epirubicin salt is epirubicin sulfate, sucrose octasulfate epirubicin, epirubicin mesylate or epirubicin mesylate; such as epirubicin sulfate.
In one embodiment of the invention, the salt solution has a concentration of 0.05M to 0.975M; for example 0.05M, 0.1M, 0.2M, 0.3M, 0.325M, 0.65M, 0.975M or 0.16M.
In one embodiment of the invention, when the salt solution is an aqueous solution of sucrose octasulfate triethylamine, the salt solution has a concentration of 0.05M to 0.3M, for example, 0.1M, 0.2M or 0.3M.
In one embodiment of the present invention, when the salt solution is an aqueous solution of triethylamine ethanedisulfonate, the salt solution has a concentration of 0.16M to 0.325M.
In one embodiment of the present invention, when the salt solution is an aqueous solution of ammonium methylsulfonate, the concentration of the salt solution is 0.325M to 0.975M.
In one embodiment of the invention, when the salt solution is an aqueous ammonium sulfate solution, the salt solution has a concentration of 0.16M to 0.325M, for example, 0.325.
In one embodiment of the present invention, in the step 1, preferably, the hydration time is related to the reaction scale, and the hydration is performed uniformly in a solution, for example, for 10 to 4 hours, for example, 10 minutes.
In one embodiment of the present invention, in the step 1, the hydration is performed in a rotary evaporator, and the rotation speed is 40-60 rp/min, for example, 50rp/min.
In one embodiment of the present invention, in the embodiment 1 of the step 2, the high-pressure homogenization is performed by using a freezing water cutting cycle at-5 to 10 ℃ in a homogenizer; preferably, the temperature of the liposome solution is ensured at 5-10 ℃.
In one embodiment of the present invention, in embodiment 1 of step 2, the high-pressure homogenizing pressure is between 800 and 1500bar, for example 1200bar.
In one embodiment of the present invention, in embodiment 1 of step 2, the number of times of high-pressure homogenization may be 3 to 4, for example, 4.
In one embodiment of the present invention, in embodiment 2 of step 2, the extrusion temperature is 35-45 ℃, for example 40 ℃.
In one embodiment of the present invention, in embodiment 2 of the step 2, the aperture of the extruded plate is 800nm,400nm,200nm or 100nm.
In one aspect of the invention, in aspect 2 of step 2, the extrusion pressure is 600 to 800psi; such as 800psi.
In a certain embodiment of the present invention, in the embodiment 2 of the step 2, the number of extrusion times may be 4 to 10, for example, 4 times.
In one embodiment of the present invention, in the embodiment 2 of the step 2, the solution A1 sequentially passes through a polycarbonate membrane filter plate having a pore diameter of 800nm,400nm,200nm or 100nm, respectively.
In one embodiment of the present invention, in embodiment 3 of step 2, the ultrasound is performed at 600W. Preferably, the ultrasound is 25 times; more preferably, the ultrasound is on for 5 seconds and off for 5 seconds.
In one aspect of the present invention, in the step 3, the molecular weight cut-off of the dialysis bag is 8000-15000; for example 10000.
In one embodiment of the present invention, in the step 3, the isotonic solution is 5% glucose or 10% sucrose aqueous solution.
In one embodiment of the present invention, in step 3, the volume ratio of the solution A2a, A2b or A2c to the isotonic solution is 1:1000.
In one embodiment of the invention, the dialysis temperature in step 3 is 0-10 ℃, e.g. 4 ℃.
In one embodiment of the invention, in step 3, the dialysis is performed for a period of time to completely remove the salt solution in the outer aqueous phase of the solution A2a, A2b or A2c liposomes, preferably for a period of time of 10-18 hours, for example 12 hours.
In a certain scheme of the invention, in the step 4, the solution A3 obtained in the step 3 and the epirubicin hydrochloride aqueous solution are mixed according to the volume ratio of 1:1, and incubating in a water bath at 50-60 ℃ for 40 minutes to obtain the ginsenoside epirubicin liposome. Specifically, the internal aqueous phase of the liposome is acid radical epirubicin insoluble salt, and the external aqueous phase of the liposome is isotonic solution.
In one embodiment of the present invention, in the step 4, the concentration of the epirubicin hydrochloride aqueous solution is 5-20 mg/mL, for example, 1mg/mL, 5mg/mL, 10mg/mL, 15mg/mL or 20mg/mL; preferably 10 to 15mg/mL.
In one embodiment of the present invention, in the step 5, the ethanol solution obtained from the ginsenoside is slowly added into the epirubicin liposome solution in the step 4, and the mixture is stirred, volatilized to remove most of the ethanol, and then placed in a dialysis bag for dialysis, and the same isotonic solution in the step 3 is used as a dialysis medium.
In one embodiment of the present invention, in the step 5, the concentration of the ginsenoside ethanol solution is 5-20 mg/mL, for example, 10mg/mL.
In one embodiment of the present invention, in the step 5, the stirring time is 30 to 60 minutes, for example, 45 minutes.
In one embodiment of the present invention, in the step 5, the molecular weight cut-off of the dialysis bag is 8000 to 15000, for example, 10000.
In one embodiment of the invention, in step 5, the dialysis is performed at a temperature of 0-10deg.C, such as 4deg.C.
In one embodiment of the invention, in step 5, the dialysis is performed for a period of time to completely remove the ethoxide solution, the uncoated epirubicin salt and the ginsenoside, preferably, the dialysis is performed for a period of time ranging from 10 to 18 hours, for example, 12 hours.
In one embodiment of the invention, in step 6, PEG-DSPE is dissolved in the same physiological isotonic solution as in step 3, and then added to the A5 lipid obtained in step 5.
In one embodiment of the present invention, in the step 6, the mass ratio of the epirubicin hydrochloride to the PEG-DSPE may be 1 (0.1-5); for example, the mass ratio of epirubicin hydrochloride to PEG-DSPE is 1:0.0.5, 1:0.1, 1:0.25, 1:0.5, 1:1 or 1:2.
In one embodiment of the invention, in step 6, the PEG-DSPE concentration is 1-20mg/mL, e.g., 10mg/mL.
The preparation method of the ginsenoside epirubicin liposome can further comprise the steps of sterilization, filtration and filling. The conditions and operations of the aseptic filtration and the filling may be those conventional in the art. For example, in the step of aseptic filtration, the liposomes are filtered using a 0.22 μm filter. In the filling step, filling in a 10mL or 20mL penicillin bottle, capping and packaging.
In one scheme of the invention, in the preparation method of the ginsenoside epirubicin liposome, the particle size D90 of the ginsenoside epirubicin liposome is less than or equal to 150nm, and the encapsulation rate is more than or equal to 80%.
The invention also provides a ginsenoside epirubicin liposome, which is prepared by the preparation method of the ginsenoside epirubicin liposome.
The invention provides a ginsenoside epirubicin liposome, which comprises the following raw materials in parts by mass: 5-15 parts of phospholipid, 0.1-4 parts of ginsenoside and 1 part of epirubicin hydrochloride; the ginsenoside epirubicin liposome does not comprise cholesterol.
In one embodiment of the present invention, preferably, the ginsenoside epirubicin liposome is prepared by the method for preparing the ginsenoside epirubicin liposome.
In one embodiment of the invention, the ginsenoside epirubicin liposome further comprises PEG-DSPE.
In one embodiment of the invention, the mass fraction of PEG-DSPE is 0.1-2 parts.
In the invention, the EG-DSPE is called polyethylene glycol-distearoyl phosphatidylethanolamine; the EG-DSPE is PEG2000-DSPE.
In one embodiment of the present invention, the salt solution may be an aqueous solution of sulfate, sulfonate or sucrose octasulfate; preferably, the salt solution is an ammonium sulfate aqueous solution, a sucrose octasulfate triethylamine aqueous solution, an ammonium methylsulfonate aqueous solution, a methyl sulfonic acid triethylamine aqueous solution, an ammonium ethanedisulfonate aqueous solution, an ammonium propanedisulfonate aqueous solution, an ethylene disulfonate triethylamine aqueous solution or an ethylene disulfonate triethylamine aqueous solution; more preferably, the salt solution is an aqueous solution of ammonium sulfate, an aqueous solution of sucrose octasulfate triethylamine, an aqueous solution of ammonium methylsulfonate or an aqueous solution of ethylene disulfonate triethylamine
In one embodiment of the present invention, the definition and mass fraction of the phospholipids and ginsenosides are as described above.
In one embodiment of the present invention, the raw materials of the ginsenoside epirubicin liposome further comprise a physiological isotonic solution and/or a saline solution.
In one embodiment of the invention, the physiological isotonic solution is a 5% dextrose aqueous solution or a 10% sucrose aqueous solution.
In one scheme of the invention, in the ginsenoside epirubicin liposome, the particle size D90 of the ginsenoside epirubicin liposome is less than or equal to 150nm, and the encapsulation rate is more than or equal to 80%.
The invention also provides a liposome composition, which comprises glucose aqueous solution and the ginsenoside epirubicin liposome.
In one embodiment of the invention, the aqueous glucose solution is a 5% aqueous glucose solution.
In one scheme of the invention, in the ginsenoside epirubicin liposome solution, the encapsulation rate of the ginsenoside epirubicin liposome is more than or equal to 80%.
In one embodiment of the present invention, the mass fractions of the phospholipid, the PEG-DSPE, the ginsenoside and the epirubicin in the ginsenoside epirubicin liposome have about 10% error due to the loss of the preparation process and the difference of the process.
The invention also provides application of the substance A in preparing a medicament for treating and/or preventing cancers; the substance A is the ginsenoside epirubicin liposome or the composition of the liposome.
In one scheme of the invention, in the application, the particle size D90 of the ginsenoside epirubicin liposome is less than or equal to 150nm, and the encapsulation rate is more than or equal to 80%.
In one embodiment of the invention, the purity of the ginsenoside is greater than or equal to 99%.
The cancer can be one or more of acute leukemia, malignant lymphoma and breast cancer.
The term "particle size D90" refers to the particle size corresponding to a sample having a cumulative particle size distribution percentage of 90%. Its physical meaning is that its particle size is less than 90% of its particle size.
In one embodiment of the present invention, the ginsenoside epirubicin lipid does not include cholesterol.
The above preferred conditions can be arbitrarily combined on the basis of not deviating from the common knowledge in the art, and thus, each preferred embodiment of the present invention can be obtained.
The reagents and materials used in the present invention are commercially available.
The invention has the positive progress effects that: the ginsenoside epirubicin liposome provided by the invention has targeting effect and drug synergistic effect on tumor cells. Taking the ginsenoside Rg3 epirubicin liposome in the example as an example, the drug effect is obviously better than that of the cholesterol epirubicin liposome; the Rg3 is proved to have better multiple functions of medicines, auxiliary materials, membrane materials, target heads and the like in the ginsenoside Rg3 epirubicin liposome, and has good medicine synergistic effect. Specifically:
(1) The drug effect is obviously improved. In particular, rg3 (1.0) -EPI-PEG/Lp group, rg3 (1.5) -EPI-PEG/Lp group, rg3 (2.0) -EPI-PEG/Lp and Rh2 (1.0) -CPT-PEG/Lp group were optimal in drug effect, wherein the high dose group (10 mg/kg) of Rg3 (1.0) -EPI-PEG/Lp, rg3 (1.5) -EPI-PEG/Lp and Rg3 (2.0) -EPI-PEG/Lp had completely disappeared tumor at day 21, with significant advantage over the cholesterol liposome control group (C-EPI-PEG/LP group). Meanwhile, the tumor inhibition rate of the medium dose group (5 mg/kg) of the three experimental groups on day 28 is 5-9%, which is better than that of the high dose group (10 mg/kg) of the cholesterol liposome control group (C-EPI-PEG/LP group) on day 28, and the Rg3 epirubicin liposome has obvious advantage on pharmacodynamics of the traditional epirubicin liposome.
(2) Glut1 targeting is significantly improved. In Glut1 targeting experiments of tumor-bearing mice, glut1 targeting of the ginsenoside liposome is improved by more than 4 times compared with that of common cholesterol liposome.
(3) The toxic and side effects are obviously reduced. Liposomes prepared according to the prescription of the present invention, rg3 epirubicin liposomes (Rg 3 (1.0) -EPI-PEG/Lp group and Rg3 (2.0) -EPI-PEG/Lp group) and Rh2 epirubicin liposomes (Rh 2 (1.0) -EPI-PEG/Lp group and Rh2 (2.0) -EPI-PEG/Lp group) all died at 40mg/kg and 60mg/kg, 80mg/kg died 1/6, 100 mg/kg; whereas the cholesterol liposome control group (C-EPI-PEG/LP group) died 2/6 at 40mg/kg, 60mg/kg all. The LD50 of Rg3 epirubicin liposome and Rh2 epirubicin liposome is 80-100mg/kg, and the LD50 of cholesterol epirubicin liposome is 40-60mg/kg, which shows that the acute toxicity of ginsenoside liposome is remarkably reduced compared with cholesterol liposome.
(4) The particle size D90 of the ginsenoside epirubicin liposome is less than or equal to 150nm, and the encapsulation rate is more than or equal to 80%.
Detailed Description
The invention is further illustrated by means of the following examples, which are not intended to limit the scope of the invention. The experimental methods, in which specific conditions are not noted in the following examples, were selected according to conventional methods and conditions, or according to the commercial specifications.
The invention is further illustrated by means of the following examples, which are not intended to limit the scope of the invention. The experimental methods, in which specific conditions are not noted in the following examples, were selected according to conventional methods and conditions, or according to the commercial specifications.
Experimental drugs and devices
Experimental drugs: 20 (S) -ginsenoside Rg3 (abbreviated as Rg 3), ginsenoside pseudo Rg3 (abbreviated as pseudo Rg 3), ginsenoside Rp1 (abbreviated as Rp 1), ginsenoside pseudo GQ (abbreviated as pseudo GQ), ginsenoside Rk1 (abbreviated as Rk 1), ginsenoside Rg5 (abbreviated as Rg 5), 20 (S) -ginsenoside Rh2 (abbreviated as Rh 2), ginsenoside Rk2 (abbreviated as Rk 2), 20 (S) -ginsenoside Rg2 (abbreviated as Rg 2), 20 (S) -ginsenoside Rh1 (abbreviated as Rh 1), 20 (S) -protopanaxadiol (abbreviated as PPD), 20 (S) -protopanaxatriol (abbreviated as PPT), epirubicin hydrochloride and the like are commercially available in the field, such as Shanghai-basic-medicine-science and technology Co, shanghai-gold and biopharmaceutical Co, shanghai-derived biological technology Co, and the like.
The molecular structural formula of the ginsenoside is as follows:
test instrument: the instruments used in the following examples were the instruments and equipment owned by Shanghai Bensu medical science and technology Co., ltd, university of double denier medical college, and the equipment model and source information were as follows:
agilent liquid chromatography: agilent 1100 set, autai 3300ELSD, agilent technologies (China) Inc.;
spin-on evaporator: ZX98-1 5L, shanghai Lu Yi Goodyear Co., ltd;
ultrasonic cleaning machine (SB 3200DT, ningbo Xinzhi biotechnology Co., ltd.);
nitrogen blowing instrument (HGC-12A, heng ao technology development Co., tianjin);
probe ultrasonic instrument (JYD-650, shanghai Zhi Xin instruments Co., ltd., china);
a high pressure homogenizer (B15, AVESTIN, canada);
mini-extruders (Avanti Polar Lipids Inc);
laser particle size analyzer (Nano ZS, markov in the united kingdom);
malvern particle sizer Malvern Nanosizer ZS (malvern, uk);
microplate reader (Thermo Scientific, waltham, MA, USA);
microplate reader (infinie 200, tecan tracking co., ltd);
flow cytometry (BD Biosciences, USA);
flow cytometry (CytoFlex S, beckman Coulter, inc., USA);
Inverted fluorescence microscopy (Leica, DMI 4000d, germany);
fluorescence microscopy (Zeiss LSM 710, oberkochen, germany);
laser confocal microscopy (Leica, DMI 4000d, germany);
confocal living microscope (Confocal intravital microscopy, IVM);
a front two-photon microscope (DM 5500Q; nikon);
a small animal living body optical imaging system (in vivo imaging system, IVIS) (PerkinElmer, USA);
biomacromolecule interactor BiaCore T200 instrument (GE, USA);
clean bench (SW-CJ-1 FD, air technologies Co., ltd.);
20L rotary evaporator: R5002K, shanghai xiafeng real company limited;
freeze dryer: FD-1D-80, shanghai Bilang instruments Co., ltd;
freeze dryer: PDFD GLZ-1B, shanghai Pudong freeze drying Equipment Co., ltd;
an electronic balance: CPA2250 (precision 0.00001 g), sidoris (Shanghai) trade Co., ltd;
an electronic balance: JY3003 (precision 0.001 g), shanghai Shunyu Hengping scientific instruments Co., ltd;
photo-electric microscope (XDS-1B, chongqing photo-electric instruments Co., ltd.);
cell incubator (CCL-170B-8, singapore ESCO).
Animals and cell lines
Animals: BALB/c nude mice are 3-4 weeks old and produced by Shanghai pharmaceutical research institute, national academy of sciences.
Tumor cell lines:
breast cancer in-situ tumor 4T1 cell line provided by university of double denier pharmacy
K562 human leukemia cells, available from Jiangsu Kaiki Biotechnology Co., ltd
SU-DHL6 lymphoma cells were purchased from Jiangsu Kaiki Biotechnology Co., ltd
Breast cancer MCF-7 cell line from Jiangsu Kaiki Biotechnology Co., ltd
The method for detecting the content of epirubicin hydrochloride comprises the following steps:
1) Chromatographic conditions: c18 column (Kromasil C18, 250X 4.6mm,5 μm)
2) Mobile phase: sodium dodecyl sulfate solution: acetonitrile: methanol=500: 500:60 (volume ratio)
Sodium dodecyl sulfonate solution: 1.44g of sodium dodecyl sulfate and 0.68mL of phosphoric acid were dissolved in 500mL of water.
3) Detection wavelength: 481nm, flow rate 1.0mL/min, column temperature 30℃and sample injection volume 10. Mu.L.
4) And (3) calculating: and recording a chromatogram, and calculating the content of epirubicin hydrochloride in the test sample solution by an external standard method.
The method for detecting the content of ginsenoside Rg3 comprises the following steps:
1) Chromatographic conditions: kromasil 100-3.5C4150mm.times.4.6 mm column.
2) Mobile phase: acetonitrile: water=55:45.
3) Detection wavelength: 203nm, a flow rate of 1mL/min, a column temperature of 35 ℃ and a sample injection amount of 10 mu L.
4) And (3) calculating: and recording a chromatogram, and calculating the Rg3 content in the test sample solution by an external standard method.
The method for detecting the encapsulation efficiency of epirubicin (or ginsenoside) comprises the following steps:
taking 2 parts of liposome samples to be detected, each of which is 0.5mL, adsorbing one part of liposome samples by a cation exchange resin column for 5min, eluting with deionized water, collecting effluent liquid in a 25mL volumetric flask, and after membrane breaking by a membrane breaker, determining the volume by the deionized water, and detecting by HPLC to obtain the drug concentration V1; the other part is placed in a 25mL volumetric flask, deionized water is used for volume determination, and the drug concentration is detected to be V0 by an HPLC method. Encapsulation efficiency = V1/v0×100%.
Short for the sake of brevity: epirubicin hydrochloride (EPI), hydrogenated phospholipid (HSPC), cholesterol (Cho), 20 (S) -ginsenoside Rg3 (Rg 3), 20 (S) -ginsenoside Rh2 (Rh 2).
Example 1: stability study of ginsenoside blank liposome in various ionic aqueous solutions
Weighing HSPC and ginsenoside with prescription amount, dissolving in 1mL chloroform by ultrasonic, concentrating under reduced pressure to dry, adding 10mL hydration solution,
hydration for 10 minutes, followed by 25 times (600W, 5 seconds on, 5 seconds off) of ultrasound, blank liposomes for each experimental group were obtained and examined for appearance and encapsulation efficiency.
3) Experimental results:
analysis of results: ginsenoside liposome is stable in neutral solution such as purified water and saccharides, but is unstable in ionic aqueous solution, namely: blank ginsenoside liposome prepared by the traditional passive drug loading method is not suitable for preparing ionic drug liposome by the traditional active drug loading method, such as epirubicin hydrochloride, epirubicin hydrochloride and the like.
Example 2 experiment of the Effect of phospholipid usage on the encapsulation efficiency of Adriamycin in the conventional active drug delivery method
Analysis of results: the ethanol injection method in the traditional active drug loading method is adopted, so that the drug-to-lipid ratio (HSPC/drug) has a larger influence on the encapsulation efficiency, and when the drug-to-lipid ratio is more than or equal to 10, the encapsulation efficiency is not obviously different. Therefore, the phospholipid ratio of the drug to the lipid of 5-15 is preferable in the present invention.
Example 3 experiment of the Effect of cholesterol usage on the encapsulation efficiency of Adriamycin in the traditional active drug delivery method
Analysis of results: by adopting the ethanol injection method in the traditional active drug-loading method, the cholesterol can improve the stability of the liposome and the encapsulation rate of the epirubicin. When cholesterol/medicine is more than or equal to 0.5, the improvement is remarkable; when cholesterol/drug is not less than 1, there is no significant difference in the amount of cholesterol to the encapsulation efficiency.
Example 4 experiment of Effect of Rg3 usage on the encapsulation efficiency of Adriamycin in conventional active drug delivery method
Analysis of results: by adopting an ethanol injection method in a traditional active drug-loading method, HSPC and Rg3 are synchronously formed into films, then an ionic aqueous solution is hydrated, 5% glucose is dialyzed and drug-loaded, and qualified Rg3 epirubicin co-loaded liposome cannot be prepared.
Example 5 experiment of Effect of cholesterol usage on Rg3 Liposome encapsulation efficiency in conventional active drug delivery method
Analysis of results: by adopting an ethanol injection method in a traditional active drug-loading method, HSPC, rg3 and cholesterol are firstly synchronously formed into films, then an ionic aqueous solution is hydrated and 5% glucose is dialyzed to obtain Rg3 liposome, and the Rg3 liposome prepared by the process has low encapsulation rate of Rg3 and Rg3 leakage is caused by the ionic aqueous solution.
Example 6 experiment of Effect of cholesterol usage on Rg3 Liposome encapsulation efficiency in conventional active drug delivery method
Analysis of results: when the external water phase is 5% glucose after dialysis by adopting an ethanol injection method in the traditional active drug loading method, rg3 is loaded into liposome as a drug, and the encapsulation rate of Rg3 is qualified, wherein the influence of the using amount of cholesterol on the encapsulation rate of Rg3 is small. Effect example 1: the results of the targeting experiments in the C6-C-Rg3 (post)/Lp group in the cell uptake experiment of Glut1 showed that: glut 1-mediated targeting was poor in this group, showing that the glucosyl group of Rg3 was not exposed at the liposome surface, and therefore Rg3 should be entrapped in the inner lumen of the liposome.
EXAMPLE 7 synchronous Loading experiment of Rg3 and epirubicin in traditional active drug-carrying method
Analysis of results: the ethanol injection method in the traditional active drug loading method is adopted, under the condition that Rg3 and cholesterol are used in different proportions, the inner water phase of the blank liposome is an ammonium sulfate solution, the outer water phase is a 5% glucose solution, rg3 and epirubicin are used as drugs, synchronous loading is carried out, and the encapsulation rates of the epirubicin and Rg3 are not qualified. The ionic aqueous solution affects both the encapsulation efficiency of Rg3 and epirubicin hydrochloride.
Example 8 experiment of the Effect of Rg 3-carried-followed-by-epirubicin on encapsulation efficiency in conventional active drug delivery method
/>
Analysis of results: the method adopts an ethanol injection method in the traditional active drug-loading method, adopts Rg3 and cholesterol in different proportions, after dialysis, the inner water phase of the blank liposome is an ammonium sulfate solution, the outer water phase is a 5% glucose solution, rg3 is loaded firstly, epirubicin hydrochloride is loaded secondly, and the encapsulation rate of the prepared Rg3 epirubicin co-loaded liposome is unqualified.
Example 9 experiment of the Effect of different preparation methods on encapsulation efficiency of Rg3 epirubicin Co-encapsulation liposomes
/>
Analysis of results:
1) Passive drug loading (thin film method) cannot prepare qualified Rg3 epirubicin co-loaded liposome;
2) The common active drug-loading method can not prepare qualified Rg3 epirubicin co-loaded liposome;
3) The common active drug loading method is to load Rg3 and then epirubicin, or the Rg3 and the epirubicin are synchronously loaded, so that qualified Rg3 epirubicin co-loaded liposome cannot be prepared;
4) The normal active drug-loading method is to load the epirubicin and then Rg3, and the qualified Rg3 epirubicin co-loaded liposome can be prepared. The liposome prepared by the method is applied in the invention to implement 1: cell uptake assay of Glut1, C6-Rg3 (post) -EPI/Lp panel assay results showed: the Rg3 liposome prepared by the method has remarkable Glut1 mediated active targeting effect, and is proved to be embedded in a phospholipid bilayer membrane, wherein the glucose group (Glc) in the Rg3 molecule is exposed on the outer surface of the liposome.
Example 10 experiment of effect of Rg3 dose on encapsulation efficiency of Rg3 epirubicin co-encapsulation liposomes
/>
Analysis of results:
1) By adopting the ethanol injection method, qualified Rg3 epirubicin co-carrier liposome can be prepared, specifically, the inner water phase of the liposome is epirubicin sulfate, the outer water phase of the liposome is 5% glucose isotonic solution, the bilayer membrane of the liposome is hydrogenated phospholipid and Rg3, wherein the glucose radical (Glc) in Rg3 molecules is exposed on the outer surface of the liposome, and the liposome membrane material does not contain cholesterol.
2) When HSPC is HSPC, rg3, EPI=10:0.1-4:1, the encapsulation efficiency of Rg3 and epirubicin is good. As the amount of Rg3 increases, the encapsulation efficiency of Rg3 and epirubicin decreases dramatically.
30 the application range of Rg3 of the invention is HSPC: rg3: epi=10:0.1 to 4:1.
EXAMPLE 11 Effect of different salts on encapsulation efficiency of Rg3 epirubicin co-encapsulation liposomes
/>
Analysis of results: by adopting the ethanol injection method, the sucrose octasulfate triethylamine, ammonium sulfate, ammonium methylsulfonate, triethylamine methylsulfonate, ammonium ethanedisulfonate, ammonium propanedisulfonate, triethylamine ethanedisulfonate and triethylamine propanedisulfonate can all meet the preparation of the Rg3 epirubicin liposome, and the encapsulation efficiency is qualified.
Example 12 experiment of the effect of different salt concentrations on the encapsulation efficiency of Rg3 epirubicin co-encapsulation liposomes
Analysis of results: when the concentration of the sucrose octasulfate triethylamine is lower than 0.05M, the ethanol injection method provided by the invention can not meet the process requirements of the encapsulation rate; when the concentration is more than or equal to 0.1M, the encapsulation efficiency is not obviously different. 2) When the concentrations of the ammonium sulfate and the ethanedisulfonic acid triethylamine are lower than 0.16M, the encapsulation efficiency cannot meet the process requirements; at concentrations of 0.32M and 0.65M, there was no significant difference in encapsulation efficiency. 3) When the concentration of ammonium methylsulfonate is lower than 0.325M, the encapsulation efficiency can not meet the process requirement; at concentrations of 0.65M and 0.975M, there was no significant difference in encapsulation efficiency.
Example 13 experiment of Effect of different ginsenosides on encapsulation efficiency of the saponin epirubicin Co-encapsulation liposomes
/>
Analysis of results: the encapsulation efficiency of the co-carried liposome prepared by the ethanol injection method of the invention, which is 20 (S) -Rg3, 20 (S) -Rh2, rg5, rk1, rp1, pseudo Rg3, pseudo GQ, PPD and other saponins, meets the quality requirements; and the encapsulation efficiency of the co-carried liposome prepared from 20 (R) -Rg3, PPT and other saponins does not meet the quality requirement.
Example 14 experiment of the Effect of different homogenization methods on encapsulation efficiency of Rg3 epirubicin co-encapsulation liposomes
Analysis of results: the ethanol injection method of the invention can meet the process requirements in three common methods (an ultrasonic method, a high-pressure homogenizing method and a push-through membrane method) for controlling the particle size.
EXAMPLE 15 Effect of different phospholipids on encapsulation efficiency of Rg3 epirubicin co-encapsulation liposomes
/>
Analysis of results: the encapsulation efficiency of the Rg3 epirubicin co-carrier liposome prepared from hydrogenated phospholipid, egg yolk lecithin, soybean phospholipid and cephalin by adopting the ethanol injection method disclosed by the invention meets the requirements of drug application, and the PEG-DSPE does not meet the requirements.
EXAMPLE 16 experiment of the effect of different epirubicin concentrations on the encapsulation efficiency of Rg3 epirubicin co-encapsulation liposomes
Analysis of results: the ethanol injection method of the invention is optimal in the case of drug concentration of 5-15 mg/mL, and particularly optimal in the case of drug concentration of 10 mg/mL. When the drug concentration is lower than 5mg/mL or higher than 20mg/mL, the encapsulation efficiency is not in compliance with the drug quality requirements.
EXAMPLE 17 Effect of different physiological isotonic solutions on encapsulation efficiency of Rg3 epirubicin co-encapsulation liposomes
Analysis of results: by adopting the ethanol injection method, the encapsulation rates of the 5% glucose and 10% sucrose aqueous solution on Rg3 and epirubicin are not obviously different, and the 0.9% physiological saline is not applicable.
EXAMPLE 18 preparation of Rg3 epirubicin liposomes
1. Prescription: 10g of HSPC, 1g of Rg3, 1g of epirubicin hydrochloride, a proper amount of absolute ethyl alcohol, a proper amount of 5% glucose injection, a proper amount of water for injection and a proper amount of 0.325M ammonium sulfate solution.
2. The operation method comprises the following steps:
step (1): film formation and hydration
Weighing HSPC with a prescription amount, dissolving the HSPC in 20mL of absolute ethyl alcohol, adding 100mL of 0.325M ammonium sulfate, hydrating for 10 minutes at 55-60 ℃, volatilizing to remove most of the ethanol, and preparing a blank liposome crude product with an internal water phase and an external water phase being ammonium sulfate solution;
step (2): push through the membrane
And (3) allowing the blank liposome solution obtained in the step (1) to sequentially pass through a polycarbonate membrane filter plate with pore diameters of 800nm, 400nm, 200nm and 100nm for 4 times under the pressure of 600-800psi, and finally obtaining the blank liposome with the particle size smaller than 100nm and the inner and outer water phases being ammonium sulfate solutions.
Step (3): dialysis
Placing the blank liposome in the step (2) in a dialysis bag with the molecular weight cut-off of 10000, dialyzing for 12 hours at 4 ℃ by taking 5% glucose aqueous solution as a dialysis medium, wherein the volume ratio of the sample to the dialysis medium is 1:1000, 1 dialysis solution is changed every 4 hours during dialysis, and ammonium sulfate in the outer water phase of the blank liposome is completely removed, so that the blank liposome with the outer water phase consisting of 5% glucose and the ammonium sulfate as the inner water phase is obtained.
Step (4): loading of epirubicin
Mixing the blank liposome in the step (3) with epirubicin hydrochloride aqueous solution with the concentration of 10mg/mL, wherein the volume ratio is 1:1, and incubating in a water bath at 50-60 ℃ for 40 minutes to obtain the epirubicin liposome. Specifically, the aqueous in-liposome phase is epirubicin sulfate insoluble salt, and the aqueous out-liposome phase is 5% glucose aqueous solution.
Step (5): embedding Rg3
Slowly adding 100mL 10mg/mL of Rg3 ethanol solution into the epirubicin liposome solution in the step (4) at 20-30 ℃, stirring for 45 minutes, volatilizing to remove most of ethanol, then placing into a dialysis bag with the molecular weight cutoff of 10000, dialyzing for 12 hours at 4 ℃ by using 5% glucose aqueous solution as a dialysis medium, wherein the volume ratio of the sample to the dialysis medium is 1:1000, changing the dialysate for 1 time every 4 hours during dialysis, and completely removing the ethanol solvent, inorganic salt, unwrapped epirubicin hydrochloride and Rg3 to obtain Rg3 epirubicin liposome.
Step (6): addition of PEG-DSPE
Accurately weighing 0.2g of PEG-DSPE, dissolving in 300mL of 5% glucose, and then adding the PEG-DSPE into the Rg3 epirubicin liposome solution in the step (5) to obtain Rg3 epirubicin liposome solution with the concentrations of both epirubicin and Rg3 being about 2 mg/mL.
Step (7) of sterilizing and filtering
The Rg3 epirubicin liposome of step (6) was filtered through a 0.22 μm filter.
Step (8): filling
Filling the solution obtained in the step (7) into a 10mL or 20mL penicillin bottle, capping and packaging to obtain the penicillin bottle.
Through detection, the liposome has the concentration of epirubicin=4.27 mg/mL, the concentration of Rg3=4.65 mg/mL, the particle size D90=104 nm, the encapsulation rate of Rg3=97.85%, and the encapsulation rate of epirubicin=96.92%.
Example 19 PE disclosure of Effect of G-DSPE usage on Rg3 epirubicin Co-carried liposome stability
The preparation method comprises the following steps: taking the Rg3 epirubicin liposome solution in the step (5) of the example 18, adding PEG-DSPE water solutions with different concentrations according to the prescription of the example, carrying out other subsequent steps in the same way as in the example 18, and then placing each prescription preparation in a refrigerator with the temperature of 2-8 ℃ to examine the stability of the liposome solution.
/>
Analysis of results:
1) PEG-DSPE is not added, after the Rg3 epirubicin liposome is stored for 3 months at the temperature of 2-8 ℃, the particle size is rapidly increased, and the leakage rate of Rg3 and epirubicin is obviously increased;
2) When PEG-DSPE/HSPC is less than or equal to 0.025, after the liposome is preserved for 3 months at 2-8 ℃, the particle size of the Rg3 epirubicin liposome is obviously increased, the encapsulation efficiency is obviously reduced, and the quality requirement of stability is not qualified. Wherein PEG-DSPE/hspc= 0.025,3 months stability data is acceptable.
3) When PEG-DSPE/HSPC is more than or equal to 0.025, after the liposome is preserved for 3 months at the temperature of 2-8 ℃, the particle size of Rg3 epirubicin liposome is stable, the encapsulation rate of Rg3 and epirubicin is more stable, and the requirements of medicine declaration are met.
4) When PEG-DSPE/HSPC is more than or equal to 0.05, the particle size and the encapsulation rate are not obviously different.
Application example 1: cell uptake assay for Glut1
1) The purpose of the experiment is as follows: observing whether the Rg3 liposomes have more uptake on tumor cells by comparing uptake of the fluorescein-loaded Rg3 liposomes with that of cholesterol liposomes on 4T1 cells; the Glut1 targeting mechanism is proved by adding glucose inhibitors and the like; the ginsenosides of the invention were confirmed to be located in the phospholipid bilayer membrane by Glut1 targeting, and the glucosyl group was exposed on the outer surface of the liposome.
2) The experimental method comprises the following steps: to compare uptake of 4T1 into each experimental group, the uptake mechanism of liposomes was examined, and 4T1 cells were used in a 2X 10 manner 5 Is inoculated in a 12-well plate, and 20mM glucose solution, phlorizin solution and quercetin solution are used for 12 hours for experimental group + glucose, experimental group + phlorizin and experimental group + quercetin group respectivelyInstead of the culture medium. The three solutes should be dissolved in glucose-free medium, after incubation for 1 hour, each experimental group of drugs (ultraviolet fluorescent developer concentration 100 ng/ml) was added, after incubation for 4 hours, digested, washed with fresh PBS solution and analyzed by flow cytometry.
3) The preparation method of the experimental group comprises the following steps: the operating conditions are the same as those of the examples of the present invention.
Method 1 (passive drug delivery): the method comprises the steps of dissolving a prescription amount of HSPC, ginsenoside and/or cholesterol, fluorescent probe (coumarin) and/or medicine in a proper amount of mixed solvent of ethanol and chloroform (volume ratio is 1:1), concentrating under reduced pressure to dryness, hydrating purified water, performing ultrasound, and detecting fluorescence intensity according to an experimental method of an application example.
Method 2 (active drug delivery): the prescribed amounts of HSPC, rg3 and fluorescent probe were sonicated in an appropriate amount of ethanol, hydrated for 10 minutes with 0.325M ammonium sulfate solution, sonicated 25 times (5 seconds on and 5 seconds off), dialyzed with 5% glucose solution, sequentially loaded with (and/or) drug, dialyzed again to remove free drug, (and/or) an appropriate amount of PEG-DSPE to obtain liposome solutions for each experimental group, and then the fluorescence intensity was detected according to the experimental method of the present application example.
Method 3 (active drug delivery): the prescribed amounts of HSPC and fluorescent probe were sonicated in appropriate amounts of ethanol, hydrated for 10 minutes with 0.325M ammonium sulfate solution, sonicated 25 times (5 seconds on and 5 seconds off), dialyzed with 5% glucose solution, then sequentially loaded with drug or Rg3, dialyzed again to remove free drug, and/or an appropriate amount of PEG-DSPE was added to obtain liposome solutions for each experimental group, and then the fluorescence intensity was detected according to the experimental method of the application example.
Experimental results 1 are as follows:
/>
conclusion of experiment:
1) The targeting experimental data prove that the traditional passive drug loading method (thin film evaporation method) is adopted: acceptable Rg3 epirubicin co-carrier liposome cannot be prepared.
2) Adopts a traditional active drug loading method, in particular:
i) Addition of Rg3 prior to dialysis, the acid radical solution caused leakage of Rg3 in the liposomes, thereby causing failure of liposome preparation.
ii) Rg3 is added after dialysis, in two cases:
a) Rg3 is added before epirubicin hydrochloride, and the ionic solution generated by the drug causes serious leakage of Rg3 in the liposome, so that the liposome preparation fails;
b) Rg3 was added after epirubicin hydrochloride and the liposome preparation was successful.
The two conditions are basically the same, and the sequence of the two conditions is different, but ionic solutions exist, different results are generated, and the mechanism is not clear.
1) The addition of PEG-DSPE in an appropriate amount affected Glut 1-mediated targeting, suggesting that the amount of PEG-DSPE was limited.
2) This experiment suggests that Rg3 epirubicin co-carrier liposomes of the present invention should be prepared in the same or similar manner as in example 18.
Experimental results 2 are as follows:
/>
from the above results, it was found that the fluorescence intensity of C6-C/Lp was not significantly changed with the addition of Glut1 substrate and inhibitor, but cellular uptake of C6-Rg3/Lp was prevented, and that ginsenoside Rg3 liposome was enhanced in uptake efficiency by interaction with Glut1, thereby demonstrating that Rg3 was located on the membrane of liposome and that the glucosyl group (Glc) of Rg3 was exposed on the surface of liposome.
Application example 2: in vivo pharmacodynamic study of human breast cancer (MCF-7)
1) The test method comprises the following steps: the tumor cell line (MCF-7) was injected subcutaneously into mice to establish a subcutaneous tumor model. When the tumor volume reaches 100mm 3 At (7 d post inoculation), mice were treated in random groups (n=8 each), each group was injected with Blank solvent (5% glucose, blank), epirubicin liposome injection (C-EPI-PEG/LP group) and each experimental group, and the doses were three groups (10 mg, 5mg, 2.5 mg) in terms of epirubicin, once every 7 days, for up to day 28, with tumor length, width and record weight measured at the same time as administration. The formula for calculating the tumor volume (V) is V= (W) 2 X L)/2. Length (L) is the longest diameter of a solid tumor and width (W) is the shortest diameter perpendicular to the length. At the end of the experiment at day 28, all animals were sacrificed and tumors were removed for imaging and histological examination.
Remarks: epirubicin+rg3=10 mg/kg+10mg/kg, representing the drug concentration, the same applies below.
2) The experimental groups were as follows:
3) The test results are as follows:
/>
conclusion:
1) Rg 3/EPI=1.0, 1.5 and 2.0, there was no significant difference in pharmacodynamics.
2) The in vivo pharmacodynamics of Rg3 epirubicin liposomes were significantly better than that of the C-EPI-PEG/LP group and Rg3 cholesterol epirubicin liposomes group (C-Rg 3 (1.0) -EPI-PEG/LP), wherein the Rg3 (1.0) -EPI-PEG/LP, rg3 (1.5) -EPI-PEG/LP and Rg3 (2.0) -high dose group of EPI-PEG/LP (10 mg/kg), tumors had completely disappeared on day 21, significantly better than that of the cholesterol liposomes control group (C-EPI-PEG/LP group). Meanwhile, the tumor inhibition rate of the medium dose group (5 mg/kg) of the three experimental groups on day 28 is 5-9%, which is better than that of the high dose group (10 mg/kg) of the cholesterol liposome control group (C-EPI-PEG/LP group) on day 28, and the Rg3 epirubicin liposome has obvious advantage on pharmacodynamics of the traditional epirubicin liposome.
Human colon cancer C-26 cell line: according to the in vivo pharmacodynamics experimental method, the study data for the in vivo pharmacodynamics of human colon cancer (C-26) cells are as follows.
The results show that:
1) The pharmacodynamics of Rg3 epirubicin liposome and Rh2 epirubicin liposome have no obvious difference;
2) The pharmacodynamics of Rg3 epirubicin liposome and Rh2 epirubicin liposome have remarkable advantages over the cholesterol liposome control group (C-EPI-PEG/LP group).
Human pancreatic cancer Capan-1: according to the in vivo pharmacodynamics experimental method, the study data for the in vivo pharmacodynamics of human pancreatic cancer (Capan-1) cells are as follows.
/>
The results show that:
1) The pharmacodynamics of Rg3 epirubicin liposome and Rh2 epirubicin liposome have no obvious difference;
2) The pharmacodynamics of Rg3 epirubicin liposome and Rh2 epirubicin liposome have remarkable advantages over the cholesterol liposome control group (C-EPI-PEG/LP group).
Application example 3: acute toxicity (LD 50) study (SD rat)
1) The experimental method comprises the following steps: rats 160-260 g, 6-9 weeks old, 6 per group, mode of administration: slow static push (about 1 mL/min), dosing frequency: 3 times per day.
The test sample contains Rg3 calculated according to the prescribed dosage, and the dosage of the test sample epirubicin is set to be 20, 40, 80 and 120 mg/kg/day. A vehicle control group (5% glucose injection), a cholesterol liposome control group (C-EPI-PEG/LP group), rg3 (1.0) -EPI-PEG/LP, rg3 (2.0) -EPI-PEG/LP, rh2 (1.0) -EPI-PEG/LP, rh2 (2.0) -EPI-PEG/LP were simultaneously set, and slow static pushing (about 1 mL/min) was performed at 3 times/day with an interval of at least 4h per administration.
2) The preparation method of the experimental group comprises the following steps: prepared according to the procedure for example 18, according to the requirements of the recipe.
3) The experimental results are shown in the following table:
it was shown by the above experiments that,
1) The acute toxicity of Rg3 epirubicin liposome and Rh2 epirubicin liposome is not obviously different;
2) Rg3 and Rh2 epirubicin liposomes (Rg 3 (1.0) -EPI-PEG/Lp group and Rg3 (2.0) -EPI-PEG/Lp group) and Rh2 epirubicin liposomes (Rh 2 (1.0) -EPI-PEG/Lp group and Rh2 (2.0) -EPI-PEG/Lp group) died at 40mg/kg and 60mg/kg, 80mg/kg died at 1/6, 100 mg/kg; whereas the cholesterol liposome control group (C-EPI-PEG/LP group) died 2/6 at 40mg/kg, 60mg/kg all. The LD50 of Rg3 and Rh2 epirubicin liposomes was 80-100mg/kg, while the LD50 of cholesterol epirubicin liposomes was 40-60mg/kg, showing that the acute toxicity of ginsenoside liposomes was significantly reduced compared to cholesterol liposomes (6/6, the number 6 at/later indicates the total number of test mice of 6, the number at/earlier indicates the number of dead mice of 6).
Claims (18)
1. The preparation method of the ginsenoside epirubicin liposome is characterized by comprising the following steps:
step 1, dissolving phospholipid in a solvent, and adding a salt solution for hydration to obtain a solution A1;
Step 2, which is scheme 1, scheme 2 or scheme 3;
scheme 1 includes the steps of:
homogenizing the solution A1 obtained in the step 1 under high pressure, and controlling the particle size D90 to be less than 100nm to obtain a solution A2a;
scheme 2 includes the steps of:
extruding the solution A1 obtained in the step 1 through all pore diameter extrusion plates in sequence, and controlling the particle diameter D90 to be less than 100nm to obtain a solution A2b;
scheme 3 includes the steps of:
carrying out ultrasonic treatment on the solution A1 obtained in the step 1 to obtain a solution A2c;
step 3, dialyzing the solution A2a, A2b or A2c obtained in the step 2 in a dialysis bag containing a physiological isotonic solution to obtain a solution A3;
step 4, mixing the solution A3 obtained in the step 3 with an aqueous solution of epirubicin hydrochloride to obtain an A4 liposome;
step 5, mixing the A4 liposome obtained in the step 4 with ginsenoside in ethanol to obtain an A5 liposome;
wherein the mass part of the phospholipid is 10, the mass part of the ginsenoside is 0.1-4, and the mass part of the epirubicin hydrochloride is 1;
the ginsenoside is selected from one or more of 20 (S) -ginsenoside Rg3, 20 (S) -ginsenoside Rh2, ginsenoside Rg5, ginsenoside Rk1, ginsenoside Rp1, pseudo Rg3, pseudo GQ and PPD;
The phospholipid is selected from one or more of hydrogenated phospholipid, egg yolk lecithin, soybean phospholipid and cephalin;
the salt solution is an ammonium sulfate aqueous solution, a sucrose octasulfate triethylamine aqueous solution, a methyl ammonium sulfonate aqueous solution, a methyl triethylamine aqueous solution, an ammonium ethane disulfonate aqueous solution, an ammonium propane disulfonate aqueous solution, an ethane disulfonate triethylamine aqueous solution or an propane disulfonate triethylamine aqueous solution;
the concentration of the ammonium sulfate aqueous solution is 0.3M-0.975M;
the concentration of the ammonium ethanedisulfonate aqueous solution is 0.16M-0.975M;
the concentration of the ammonium malonate aqueous solution is 0.16M-0.975M;
the concentration of the aqueous solution of the triethylamine ethanedisulfonate is 0.3M-0.975M;
the concentration of the aqueous solution of the trisodium propanedisulfonate is 0.16M-0.975M;
the concentration of the sucrose octasulfate triethylamine aqueous solution is 0.1M-0.975M;
the concentration of the ammonium methylsulfonate aqueous solution is 0.65M-0.975M;
the concentration of the aqueous solution of the triethylamine methylsulfonate is 0.325M-0.975M;
in the step 3, the isotonic solution is 5% glucose or 10% sucrose aqueous solution.
2. The method for preparing the ginsenoside epirubicin liposome according to claim 1, wherein,
The concentration of the ammonium sulfate aqueous solution is 0.3M, 0.325M, 0.65M or 0.975M;
the concentration of the ammonium ethanedisulfonate aqueous solution is 0.16M, 0.2M, 0.3M, 0.325M, 0.65M or 0.975M;
the concentration of the ammonium malonate aqueous solution is 0.16M, 0.2M, 0.3M, 0.325M, 0.65M or 0.975M;
the concentration of the aqueous solution of the triethylamine ethanedisulfonate is 0.3M, 0.325M, 0.65M or 0.975M;
the concentration of the aqueous solution of the trisethylamine malonate is 0.16M, 0.2M, 0.3M, 0.325M, 0.65M or 0.975M;
the concentration of the sucrose octasulfate triethylamine aqueous solution is 0.1M, 0.2M, 0.3M, 0.325M, 0.65M, 0.975M or 0.16M;
the concentration of the ammonium methylsulfonate aqueous solution is 0.65M or 0.975M;
the concentration of the aqueous solution of the triethylamine methylsulfonate is 0.325M, 0.65M or 0.975M.
3. The method for preparing the ginsenoside epirubicin liposome according to claim 1, wherein,
the phospholipid is hydrogenated phospholipid or egg yolk lecithin;
and/or the mass ratio of the epirubicin hydrochloride to the ginsenoside is 1:1 or 1:1.5;
and/or the ginsenoside is selected from one or more of 20 (S) -ginsenoside Rg3, 20 (S) -ginsenoside Rh2, ginsenoside Rg5, ginsenoside Rk1 and ginsenoside Rp 1;
And/or the salt solution is an ammonium sulfate aqueous solution, a sucrose octasulfate triethylamine aqueous solution, an ammonium methylsulfonate aqueous solution or an ethylene disulfonate triethylamine aqueous solution;
and/or, the HPLC purity of the ginsenoside is more than or equal to 99%;
and/or the volume-mass ratio of the salt solution to the epirubicin hydrochloride is 66.7-200 mL/g;
and/or, when the salt solution is sucrose octasulfate triethylamine water solution, the concentration of the salt solution is 0.1M-0.3M;
and/or when the salt solution is an aqueous solution of triethylamine ethanedisulfonate, the concentration of the salt solution is 0.3M-0.325M;
and/or, when the salt solution is an ammonium methylsulfonate aqueous solution, the concentration of the salt solution is 0.65M-0.975M;
and/or, when the salt solution is an ammonium sulfate aqueous solution, the concentration of the salt solution is 0.3M-0.325M.
4. The method for preparing ginsenoside epirubicin liposome according to claim 3, wherein when the salt solution is sucrose octasulfate triethylamine aqueous solution, the concentration of the salt solution is 0.1M, 0.2M or 0.3M;
and/or, when the salt solution is an ammonium sulfate aqueous solution, the concentration of the salt solution is 0.325M.
5. The method for preparing the ginsenoside epirubicin liposome according to claim 1, wherein,
the mass fraction of the ginsenoside is 1 part;
and/or the ginsenoside is 20 (S) -ginsenoside Rg3 or 20 (S) -ginsenoside Rh2;
and/or the salt solution is an ammonium sulfate aqueous solution;
and/or the volume-mass ratio of the salt solution to the epirubicin hydrochloride is 100mL/g.
6. The method for preparing a ginsenoside epirubicin liposome according to any one of claims 1 to 5, wherein the method for preparing a ginsenoside epirubicin liposome further comprises the step 6: dispersing the A5 liposome and PEG-DSPE obtained in the step 5 in a physiological isotonic solution to obtain the ginsenoside epirubicin liposome;
and/or, in the step 1, the solvent is ethanol;
and/or in the step 1, the mass-volume ratio of the phospholipid to the solvent is 1 g/1-10 mL;
and/or, in the step 1, the hydration temperature is 55-65 ℃;
and/or the hydration time is related to the reaction scale, and the hydration is uniform in solution;
and/or, in the step 1, the hydration is carried out in a rotary steaming bottle, and the rotating speed is 40-60 rp/min;
And/or in the scheme 1 of the step 2, the high-pressure homogenization is carried out by using a freezing water cutting cycle at the temperature of-5-10 ℃ in a homogenizer;
and/or, in scheme 1 of step 2, the high pressure homogenizing pressure is between 800 and 1500 bar;
and/or, in the scheme 1 of the step 2, the number of times of high-pressure homogenization is 3-4 times;
and/or, in the step 2, the extrusion temperature is 35-45 ℃;
and/or, in the step 2, in the scheme 2, the aperture of the extrusion plate is 800nm,400nm,200nm or 100nm;
and/or, in scheme 2 of step 2, the extrusion pressure is 600-800 psi;
and/or, in the step 2, the number of times of extrusion is 4-10 times;
and/or, in the step 2 of the scheme 2, the solution A1 sequentially passes through a polycarbonate membrane filter plate with the pore diameter of 800nm,400nm,200nm or 100nm respectively;
and/or, in the step 2 of the solution 3, the ultrasound at 600W;
and/or, the ultrasound is 25 times;
and/or, in the step 3, the molecular weight cut-off of the dialysis bag is 8000-15000;
and/or in the step 3, the volume ratio of the solution A2a, A2b or A2c to the isotonic solution is 1:1000;
And/or, in the step 3, the temperature of the dialysis is 0-10 ℃;
and/or, in step 3, said dialysis is performed for a time to completely remove said salt solution in the outer aqueous phase of said solution A2a, A2b or A2c liposomes;
and/or, in the step 4, the concentration of the epirubicin hydrochloride aqueous solution is 5-20 mg/mL;
and/or in the step 5, the concentration of the ginsenoside ethanol solution is 5-20 mg/mL;
and/or, in the step 5, the mixing time is 30-60 minutes;
and/or, in the step 5, the molecular weight cut-off of the dialysis bag is 8000-15000;
and/or, in step 5, the dialysis temperature is 0-10 ℃;
and/or, in step 5, the dialysis is performed for a period of time based on complete removal of the ethanolate solution, the non-encapsulated epirubicin and the ginsenoside;
and/or, the preparation method of the ginsenoside epirubicin liposome further comprises the steps of sterilization, filtration and filling;
and/or, in the preparation method of the ginsenoside epirubicin liposome, the particle size D90 of the ginsenoside epirubicin liposome is less than or equal to 150nm, and the encapsulation rate is more than or equal to 80%.
7. The method for preparing ginsenoside epirubicin liposome according to claim 6, wherein in the step 1, the solvent is absolute ethanol;
And/or, in the step 1, the mass-volume ratio of the phospholipid to the solvent is 1g/2mL;
and/or, in the step 1, the hydration is carried out in a rotary steaming bottle, and the rotating speed is 50 rp/min;
and/or in the scheme 1 of the step 2, the high-pressure homogenization is carried out by using a freezing water cooling cutting cycle at 5-10 ℃ in a homogenizer;
and/or, in the step 2 of the scheme 1, the high pressure homogenizing pressure is 1200bar;
and/or, in the step 2 of the scheme 1, the number of times of high-pressure homogenization is 4;
and/or, in the step 2, in the scheme 2, the extrusion temperature is 40 ℃;
and/or, in scheme 2 of step 2, the extrusion pressure is 800 psi;
and/or, in the step 2 of the scheme 2, the number of times of extrusion is 4 times;
and/or, the ultrasonic is started for 5 seconds and stopped for 5 seconds;
and/or, in the step 3, the molecular weight cut-off of the dialysis bag is 10000;
and/or, in step 3, the dialysis temperature is 4 ℃;
and/or, in step 3, the dialysis time is 10-18 hours;
and/or, in the step 4, the concentration of the epirubicin hydrochloride aqueous solution is 5mg/mL, 10mg/mL, 15mg/mL or 20mg/mL;
And/or, in the step 5, the concentration of the ginsenoside ethanol solution is 10mg/mL;
and/or, in the step 5, the mixing time is 45 minutes;
and/or, in the step 5, the molecular weight cut-off of the dialysis bag is 10000;
and/or, in step 5, the dialysis temperature is 4 ℃;
and/or, in step 5, the dialysis is for 10-18 hours;
and/or, when the preparation method of the ginsenoside epirubicin liposome further comprises the steps of sterilization filtration and filling, in the sterilization filtration step, a 0.22 mu m filter membrane is adopted to filter the liposome; in the filling step, filling in a 10mL or 20mL penicillin bottle, capping and packaging;
and/or, when the preparation method of the ginsenoside epirubicin liposome further comprises the step 6, in the step 6, dissolving PEG-DSPE in the same physiological isotonic solution in the step 3, and then adding the PEG-DSPE into the A5 lipid obtained in the step 5;
and/or in the step 4, the solution A3 obtained in the step 3 and the epirubicin hydrochloride aqueous solution are mixed according to the volume ratio of 1:1, mixing and incubating in a water bath at 50-60 ℃ for 40 minutes to obtain the epirubicin liposome;
And/or, in the step 5, slowly adding the ethanol solution of the ginsenoside into the epirubicin liposome solution in the step 4, stirring, volatilizing to remove most of ethanol, and then placing into a dialysis bag for dialysis, wherein the same isotonic solution in the step 3 is used as a dialysis medium;
and/or, when the preparation method of the ginsenoside epirubicin liposome further comprises the step 6, in the step 6, the mass ratio of the epirubicin hydrochloride to the PEG-DSPE is 1 (0.1-5);
and/or, when the preparation method of the ginsenoside epirubicin liposome further comprises the step 6, in the step 6, the concentration of the PEG-DSPE is 1-20mg/mL.
8. The method for preparing ginsenoside epirubicin liposome of claim 6, wherein the hydration time is 10 minutes;
and/or, in step 3, the dialysis time is 12 hours;
and/or, in the step 4, the concentration of the epirubicin hydrochloride aqueous solution is 10-15 mg/mL;
and/or, in step 5, the dialysis is performed for 12 hours.
9. The method of claim 6, wherein when the method of preparing a ginsenoside epirubicin liposome further comprises step 6, the mass ratio of the epirubicin hydrochloride to the PEG-DSPE is 1:0.0.5, 1:0.1, 1:0.25, 1:0.5, 1:1 or 1:2;
And/or, when the preparation method of the ginsenoside epirubicin liposome further comprises the step 6, in the step 6, the concentration of the PEG-DSPE is 10mg/mL.
10. A ginsenoside epirubicin liposome prepared by the method for preparing the ginsenoside epirubicin liposome according to any one of claims 1-9.
11. The ginsenoside epirubicin liposome is characterized by comprising the following raw materials in parts by mass: 10 parts of phospholipid, 0.1-4 parts of ginsenoside and 1 part of epirubicin hydrochloride; the ginsenoside epirubicin liposome does not comprise cholesterol;
the ginsenoside epirubicin liposome is prepared by the preparation method of the ginsenoside epirubicin liposome according to any one of claims 1-9.
12. The ginsenoside liposome of claim 11, wherein the ginsenoside epirubicin liposome further comprises PEG-DSPE, and the PEG-DSPE mass fraction is 0.1-2 parts.
13. The ginsenoside liposome of claim 12, wherein the PEG-DSPE is PEG2000-DSPE.
14. The ginsenoside epirubicin liposome of claim 11, wherein the particle size d90% of the ginsenoside epirubicin liposome is less than or equal to 150nm, and the encapsulation efficiency is more than or equal to 80%.
15. A liposome composition comprising an aqueous solution of glucose and the ginsenoside epirubicin liposome of any one of claims 10-14.
16. The liposomal composition of claim 15 wherein the aqueous glucose solution is a 5% aqueous glucose solution;
and/or, in the ginsenoside epirubicin liposome solution, the encapsulation rate of the ginsenoside epirubicin liposome is more than or equal to 80 percent.
17. Use of a substance a for the preparation of a medicament for the treatment and/or prophylaxis of cancer, wherein the substance a is a ginsenoside epirubicin liposome according to any one of claims 10 to 14 or a composition of liposomes according to claim 15.
18. The use of claim 17, wherein the cancer is one or more of acute leukemia, malignant lymphoma, and breast cancer;
and/or the particle diameter D90 of the ginsenoside epirubicin liposome is less than or equal to 150nm, and the encapsulation rate is more than or equal to 80%;
And/or, in the application, the purity of the ginsenoside is more than or equal to 99 percent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110652144.5A CN115444822B (en) | 2021-06-09 | 2021-06-09 | Ginsenoside epirubicin liposome, and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110652144.5A CN115444822B (en) | 2021-06-09 | 2021-06-09 | Ginsenoside epirubicin liposome, and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115444822A CN115444822A (en) | 2022-12-09 |
| CN115444822B true CN115444822B (en) | 2024-02-27 |
Family
ID=84295306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110652144.5A Active CN115444822B (en) | 2021-06-09 | 2021-06-09 | Ginsenoside epirubicin liposome, and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115444822B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106466299A (en) * | 2015-08-19 | 2017-03-01 | 上海本素医药科技有限公司 | Blank liposome with ginsenoside as membrane material, its preparation method and application |
| CN106511274A (en) * | 2016-11-28 | 2017-03-22 | 南昌大学 | Ginsenoside Rh2 ester lipidosome and preparation method and application |
| WO2020108600A1 (en) * | 2018-11-29 | 2020-06-04 | Shanghai Ginsome Pharmatech Co., Ltd. | A novel blank liposome with ginsenoside rg3 or its analog as membrane materials and preparations and uses thereof |
-
2021
- 2021-06-09 CN CN202110652144.5A patent/CN115444822B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106466299A (en) * | 2015-08-19 | 2017-03-01 | 上海本素医药科技有限公司 | Blank liposome with ginsenoside as membrane material, its preparation method and application |
| JP2018528269A (en) * | 2015-08-19 | 2018-09-27 | シャンハイ ギンポサム ファーマテック カンパニー リミテッド | Liposome having ginsenoside as membrane material and preparation and use thereof |
| CN106511274A (en) * | 2016-11-28 | 2017-03-22 | 南昌大学 | Ginsenoside Rh2 ester lipidosome and preparation method and application |
| WO2020108600A1 (en) * | 2018-11-29 | 2020-06-04 | Shanghai Ginsome Pharmatech Co., Ltd. | A novel blank liposome with ginsenoside rg3 or its analog as membrane materials and preparations and uses thereof |
| CN111228219A (en) * | 2018-11-29 | 2020-06-05 | 上海参素药物技术有限公司 | Blank liposome taking ginsenoside Rg3 or analogues thereof as membrane material, preparation method and application thereof |
| CN111956614A (en) * | 2018-11-29 | 2020-11-20 | 上海参素药物技术有限公司 | Paclitaxel liposome and preparation method thereof |
Non-Patent Citations (4)
| Title |
|---|
| Multifunctional ginsenoside Rg3-based liposomes for glioma targeting therapy;Zhu et al.;《Journal of Controlled Release》;第330卷;第641页摘要，第642页第2.2节第1段，第652和655页第4节Conclusion部分 * |
| Paclitaxel-loaded ginsenoside Rg3 liposomes for drug-resistant cancer therapy by dual targeting of the tumor microenvironment and cancer cells;Zhu et al.;《Journal of Advanced Research》;第49卷;第159-173页 * |
| Zhu et al..Multifunctional ginsenoside Rg3-based liposomes for glioma targeting therapy.《Journal of Controlled Release》.2020,第330卷第641页摘要，第642页第2.2节第1段，第652和655页第4节Conclusion部分. * |
| 胆固醇在脂质体中作用及甾醇、皂苷对其替换的研究进展;陈李霞等;《中草药》;第51卷(第24期);第6396-6404页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115444822A (en) | 2022-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gouda et al. | Ethanol injection technique for liposomes formulation: An insight into development, influencing factors, challenges and applications | |
| CN109833298B (en) | Novel blank liposome taking ginsenoside derivative as membrane material, preparation method and application thereof | |
| EP2415464B1 (en) | Method for producing liposome composition | |
| US20060034908A1 (en) | Manufacturing process for liposomal preparations | |
| AU2010312078B2 (en) | Liposome having inner water phase containing sulfobutyl ether cyclodextrin salt | |
| CA2673924A1 (en) | Liposomal pharmaceutical preparation and method for manufacturing the same | |
| Yang et al. | Coencapsulation of epirubicin and metformin in PEGylated liposomes inhibits the recurrence of murine sarcoma S180 existing CD133+ cancer stem-like cells | |
| WO2012072006A1 (en) | Liposome lyophilized composition of water soluble drug and preparation process thereof | |
| EP3643299A1 (en) | Biological self-assembled nanocrystal injection having lymphatic targeting function and preparation method | |
| US11357728B2 (en) | Liposome having inner water phase containing sulfobutyl ether cyclodextrin salt | |
| CN103479578A (en) | Pixantrone maleate liposome preparation and preparation process thereof | |
| CN102485211A (en) | Doxorubicin liposome and its preparation method | |
| CN106727329A (en) | Temperature-sensitive nanoparticle formulations and preparation method thereof | |
| CN105832670A (en) | Technology for preparing double-loaded or multi-loaded liposome through liposome fusion induction | |
| KR20080094473A (en) | Anionic lipid nanosphere and preparation method of the same | |
| CN106821987B (en) | Liposome carrying phenol hydroxyl group-containing insoluble drug, and preparation method and application thereof | |
| CN115444822B (en) | Ginsenoside epirubicin liposome, and preparation method and application thereof | |
| EP2656849A1 (en) | Liposome comprising combination of chloroquine and adriamycin and preparation method thereof | |
| CN105287612B (en) | Salinomycin Sodium and adriamycin nano liposome and the preparation method and application thereof are carried altogether | |
| Zhang et al. | Contrastive Studies of Cytarabine/Daunorubicin Dual-Loaded Liposomes Prepared by pH Gradient and Cu 2+ Gradient Method | |
| CN115444821B (en) | Ginsenoside vincristine liposome, and preparation method and application thereof | |
| EP4353223A1 (en) | Application of pharmaceutical composition having specific drug-to-lipid ratio in antitumor | |
| KR101484080B1 (en) | Method for preparing liposome preparation containing amphotericin b with increased entrapment efficiency and improved storage stability, and liposome preparation obtained therefrom | |
| CN105055318B (en) | A kind of dual target liposome and its preparation method and application modified with MAN and WGA | |
| CN102188378A (en) | Preparation method of liposome for coating and carrying water soluble drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |